New Onset Arthritis. Clinical Dilemmas in Arthritis and Rheumatology. Physical Examination. Other Pertinent History
|
|
- Garry Lucas
- 5 years ago
- Views:
Transcription
1 New Onset Arthritis Clinical Dilemmas in Arthritis and Rheumatology Primary Care Principles and Practice October 2008 Jonathan Graf, MD Assistant Professor of Medicine, UCSF Division of Rheumatology, SFGH 34 year old female presents to your office complaining of 6-7 weeks of low grade fevers, fatigue, flu like symptoms, and pain in her hands, wrists, feet and right knee. There is morning stiffness in her hands that lasts for about an hour and is relieved with activity. Over the counter naproxen relieves some but not all of her symptoms. Other Pertinent History Past medical history: hepatitis C Family history: mother with hypothyroidism Social history: ½ PPD smoking for 15 years Medications: Naproxen prn Physical Examination Well appearing young female No rashes, oral ulcers, alopecia Normal chest and cardiovascular exam Musculo-skeletal: synovial swelling and tenderness in her wrists, MCPs, PIPs. + pain with squeezing of MTPs. + Warm right knee with small effusion 1
2 Laboratory Tests CBC: Mild thrombocytosis Chem panel: WNL LFTs: Mild elevation of ALT only ANA + 1:80 (normal less than 40) RF (normal less than 20) Anti-CCP antibodies: +35 (normal <20) ESR: 56 (normal <20) hscrp: 14.7 (normal <0.3) HCV +, HBSag neg Radiographs Subtle soft tissue swelling MCPs and PIPs Periarticular osteopenia No significant joint space narrowing, erosions, or deformities Question #1 Which of the following statements regarding this patient is correct? A. This patient has hepatitis C associated arthritis B. This patient has Rheumatoid Arthritis C. This patient has arthritis associated with lupus because her ANA is positive D. The patient s diagnosis is unclear at this point because it is too early to differentiate her arthritis from a viral/parvoviral arthritis Question #1 Which of the following statements regarding this patient is correct? A. This patient has hepatitis C associated arthritis B. This patient has Rheumatoid Arthritis C. This patient has arthritis associated with lupus because her ANA is positive D. The patient s diagnosis is unclear at this point because it is too early to differentiate her arthritis from a viral/parvoviral arthritis 2
3 Why this patient likely has RA A. This patient does not have hepatitis C associated arthritis Hepatitis C infection is associated with a polyarticular arthropathy Generally athralgias > frank inflammatory arthritis (if inflammation present, usually mild) Rheumatoid Factor is non specific for RA. Majority of HCV patients are RF+ and usually high titer Usually non-erosive arthropathy Why this patient likely has RA C. This patient does not have arthritis associated with lupus because her ANA is positive ANA is non specific for Lupus and can be seen in RA & other CVD Lack of other clinical features of SLE Presence of thrombocytosis rather than thrombocytopenia This patient has EARLY RA D. It is not too early to differentiate her arthritis from a viral/parvoviral arthritis - The diagnosis of RA can be tricky - ACR criteria for RA stress that arthritis symptoms be present for >=6 weeks - Helps differentiate from viral arthritis - Symptoms frequently insidious in onset - Up to 50% can be RF negative at presentation ACR Criteria for the Classification of Rheumatoid Arthritis (>4 criteria required; 1-4 must be present > 6 wks) Morning stiffness > 1 hr Arthritis of 3 or more joint areas Arthritis of wrists, MCPs, and/or PIPs Symmetric arthritis Rheumatoid nodules Serum rheumatoid factor Radiographic changes 3
4 Limitations of ACR Classification Criteria for the diagnosis of early RA Developed for the classification of patients with longstanding disease For early RA: Specificity: 90% Limited sensitivity: 40-65% Diagnosis of early RA by ACR criteria van Gaalen et al Arth Rheum 50: 709, patients with early inflammatory arthritis Initial evaluation After 3 years 205 RA by ACR criteria undifferentiated 127 RA arthritis 413 other diagnoses RA: classic presentation Female in third or fourth decade of life Insidious onset Persistent Inflammatory polyarthritis AM stiffness (hours) Symmetric Hand involvement Rheumatoid factor Question II Which of her following clinical features is most specific for her diagnosis of Rheumatoid Arthritis? A. Her positive anti-ccp antibodies (35: normal<20) B. Her high titer RF titer (1:2560: normal <20) C: Her hscrp is elevated (14.7: normal <0.3) D. The presence of synovitis on exam 4
5 Question II Which of her following clinical features is most specific for her diagnosis of Rheumatoid Arthritis? A. Her positive anti-ccp antibodies (35: normal<20) B. Her high titer RF titer (1:2560: normal <20) C: Her hscrp is elevated (14.7: normal <0.3) D. The presence of synovitis on exam Question II: Other Answers RF is non specific and highly associated with hepatitis C hscrp is non specific marker of inflammation Many causes of inflammatory arthritis can cause elevated hscrp Synovitis can be seen in many CVD, viral arthritis, etc Our Patient with Early RA: Sensitivity and Specificity Problem Sensitivity: ACR criteria lack relative sensitivity in early RA Delay the diagnosis and initiation of therapy Specificity: RF and inflammatory markers are not specific enough in this patient with HCV Diagnosis of early RA by ACR criteria van Gaalen et al Arth Rheum 50: 709, patients with early inflammatory arthritis Initial evaluation After 3 years 205 RA by ACR criteria undifferentiated 127 RA arthritis 413 other diagnoses 5
6 Factors predictive of progression from undifferentiated arthritis to RA van Gaalen et al Arth Rheum 50: 709, 2004 At initial evaluation OR (95% CI) Positive rheumatoid factor 1.7 ( ) Positive anti-ccp antibody 38.6 ( ) Posttranslational modification of proteins: PADI converts arginine to citrulline RA-associated autoantibodies that recognize peptides containing citrulline Girbal-Neuhauser et al J Immunol 162: 585, 1999 Peptide sequence Antibody recognition Antibodies to citrullinated peptides in RA Detected by ELISAs using synthetic cyclic citrullinated peptides (CCP) ESSRDGSRHPRSHD PADI ESSRDGScitHPRSHD No Yes Sensitivity for early RA: 50% Sensitivity for later RA: 70-80% Specificity for RA: 95-98% 6
7 Anti-CCP Antibodies are Specific for RA vs. Hepatitis C Wener et al. Arthritis Rheum Jul;50(7): RF and anti-ccp testing in a cohort of 182 early RA patients Quinn et al Rheumatology (Oxford) 45:478, 2006 RF+CCP- RF-CCP- RF-CCP+ RF+CCP+ Clinical utility of the anti-ccp antibody test Diagnosis: Clinical suspicion of rheumatoid arthritis Undifferentiated inflammatory arthritis Distinguish RA from other RF + polyarthritis Not useful to monitor disease activity Best single predictor for destructive disease in patients with early onset RA Progression of joint damage in subgroups of early RA Huizinga et al Arthritis Research& Therapy 7: 949, 2005 radiographic joint damage score anti-ccp + anti-ccp - 7
8 Question III The next best step in this patient s management would be A. To start an NSAID and advance to a DMARD in 2-3 months if not adequately controlled B. To start methotrexate immediately C. To check her hepatitis C viral load, and if less than 10 4 copies/ml, then start methotrexate D. None of the above Question III The next best step in this patient s management would be A. To start an NSAID and advance to a DMARD in 2-3 months if not adequately controlled B. To start methotrexate immediately C. To check her hepatitis C viral load, and if less than 10 4 copies/ml, then start methotrexate D. None of the above Points specific to Question III This is obviously a challenging case RA: Chronic Joint Destruction and Disability What We Try to Prevent 1. NSAIDs are no longer the standard of care for first line therapy of RA a DMARD is 2. Hepatitis C is a contraindication to use of methotrexate. 3. If MTX absolutely must be used, done in conjunction with liver biopsy: Hep C viral load of no utility 8
9 Early RA: The Window of Opportunity to Intervene Joint damage in RA: progressive narrowing and erosion of a MCP joint At presentation: 1 year 5 years normal Irreversible damage can develop within months of onset of RA 1 year prior to 6 months after 3 years after onset onset of RA onset of symptoms of symptoms Radiographic changes in the same joint over time The Window of Opportunity Eventually Closes for Many. Chronic disease progression leads to permanent joint deformity, destruction, and disability Empirically, RA is a different disease the longer disease activity progresses without effective control More difficult to suppress activity and treat More extra-articular disease? 9
10 Treatment of early RA Effective treatment should be started when the diagnosis is made Effective treatment = therapies shown to slow joint destruction Goal is to induce and then maintain remission Combination of drugs more effective than monotherapy Ra: Traditional Treatment Paradigm Pyramid of therapy Start conservatively Gradually ascend the pyramid in order of potency and toxicity of therapy Only the most severely affected patients receive immuno-supressive, DMARDs DMARD therapy begun only after period of significant delay Re-Thinking the RA Treatment Pyramid Emphasizes earlier diagnosis and initiation of therapy with disease modifying anti-rheumatic drugs ACR RA Practice Guidelines 2002 Most patients with Rheumatoid Arthritis should be evaluated expeditiously Treatment with DMARD instituted within 3 months of diagnosis Goals are to prevent or control joint damage, prevent loss of function, and decrease pain 10
11 DMARD Therapies Methotrexate Leflunomide (Arava) Sulfasalazine Azathioprine Mycophenolate Mofetil Corticosteroids Hydroxychloroquine Minocycline Combination DMARD Therapies: Some Step Up Methotrexate Prednisone +/- Sulfasalazine +/- Plaquenil Methotrexate X Lefl. Generally not done Combination DMARD Therapies: Others Step Down Combination DMARD Therapies: Others Step Down Methotrexate +SSZ +Plaquenil +/- Prednisone Methotrexate +SSZ +Plaquenil 11
12 Combination DMARD Therapies: Others Step Down Why Move Towards Combination Regimens with Biologics?? Methotrexate For many RA patients, DMARDs alone effectively control symptoms For others not contolled, addition/combination of anti TNF biologic therapy is being instituted earlier The Current Pyramid Paradigm DMARD Options for our Patient Methotrexate Leflunomide (Arava) Sulfasalazine Low dose corticosteroids Azathioprine Minocycline Early initiation and titration of DMARD If incomplete response to DMARD alone, after reasonable titration, addition of biologic recommended 12
13 Is there anything else to offer this patient: Biologic Therapies?? Anti-Tnf medications Etanercept (cytokine receptor fusion protein) Infliximab (anti-cytokine antibody) Adalimumab (anti-cytokine antibody) B-cell depleting agents (monoclonal antibody) Rituximab T-cell costimulation inhibitors (receptor-ligand ) Abatacept Il-1 Inhibitors (Il-1 cytokine receptor decoy) Anakinra Is there anything else to offer this patient: Biologic Therapies?? Anti-Tnf medications Etanercept (cytokine receptor fusion protein) Infliximab (anti-cytokine antibody) Adalimumab (anti-cytokine antibody) B-cell depleting agents (monoclonal antibody) Rituximab T-cell costimulation inhibitors (receptor-ligand ) Abatacept Il-1 Inhibitors (Il-1 cytokine receptor decoy) Anakinra Anti TNF Therapy & Hepatitis C TNF appears to be implicated in chronic liver injury rather than having protective anti-viral effects Some clinical evidence to support benefit in HCV cirrhosis Interval monitoring of LFTs recommended Summary of Observational Studies in RA with Hepatitis C: Study Year n Mean f/u (months) Peterson et al Park and Reveille Ferri et al Earlier studies: etanercept and infliximab. More recent include some patients on Adalimumab All studies show no increase in transaminases or viral load 1. Ann Rheum Dis Nov;62(11): Arthritis Rheum Oct 15;51(5): J Rheumatol Oct;35(10):
14 This is a Challenging Case of Early Rheumatoid Arthritis Timely recognition is challenging Hepatitis C arthritis can mimic RA (especially mild RA) and confound specificity of diagnosis Hepatitis C is highly associated with RF+ which also confounds diagnosis Using ACR criteria alone will miss many patients with early RA Prompt treatment with DMARD therapy is absolutely essential to prevent long term complications Hepatitis C status complicates therapeutic choices Early RA Dilemmas: Summary RA can be difficult to diagnose early in its course Problematic because early DMARD treatment is essential for long term benefits Anti-CCP antibody assay very beneficial in differentiating RA from other causes of inflammatory arthritis and Hep C arthritis Needs to be used in right clinical context for maximum positive predictive value Negative predictive value lower, especially in early RA Prognostic potential if anti-ccp + Difficult RA Dilemmas: Summary Early initiation of DMARD essential Hep C + precludes use of most DMARDs that are potentially hepatotoxic: eg. MTX Hepatitis antibody status usually checked before initiating methotrexate, leflunomide, etc. Also counsel about birth control and ETOH abstinence Sulfasalazine appropriate DMARD to start, but might not be strong enough Use of anti-tnf therapy in RA patients with Hep C is now being tried, although further long term studies needed La Cortisone: Raul Dufy 14
15 Case II: A Chest Full of Questions 46 year old female diagnosed 14 years ago with SLE when she presented with proteinuria, skin rashes, oral ulcers, and a polyarticular arthrtitis in her hands. ANA +, anti-dsdna+, and anti-smith +. Initially treated with prednisone, hydroxychloroquine, and azathioprine with success. Case II continued Intermittently, she d report flares of fatigue, pleuritic chest pains, oral ulcers, arthritis and rashes a few times/year, treated by her medication and corticosteroid dosages. Over the past 4 months, she notes episodes of dyspnea on exertion, intermittent chest pain, especially when she s breathing heavily, and fatigue. Case II, continued Past medical history is as described Habbits: smokes ½ PPD X 20 years, occasional ETOH, no illicit drug use Medications: methotrexate (for past 6 months), prednisone, & hydroxychloroquine 15
16 Case II, physical exam HEENT: malar erythema, no oral ulcerations Chest: slight dullness at left lung base but lung fields are generally clear CV: regular rate, rhythm, +s4, no murmurs, no audible rubs ABD: NT/ND without hepatosplenomegaly EXT: No edema Skin: No other rashes Musculokeletal: no synovitis Subacute Chest Pain and SLE The least useful test in working up this patient s symptoms is which of the following: A. CXR B. EKG, cardiac stress testing C. Anti-ds DNA Ab. Titer D. Echocardiogram E. CT angiography Subacute Chest Pain and SLE The least useful test in working up this patient s symptoms is which of the following: A. CXR B. EKG, cardiac stress testing C. Anti-ds DNA Ab. Titer D. Echocardiogram E. CT angiography Etiologies of Chest pain in SLE Pleuritis: Exudative pleural effusion Pneumonia: SLE patients are doubly susceptible to infectious complications from SLE, itself from the use of immunosupressive therapies 16
17 Other pulmonary complications Methotrexate hypersensitivity (top right) Fever, cough, SOB, flu Interstitial infiltrates and fibrosis Lupus associated acute pneumonitis (rare) Chronic ILD Boop, UIP, NSIP Diffuse alveolar hemorrhage Shrinking lung syndrome (bottom right) Pericarditis and SLE Most common cardiac manifestation 18% in Hopkins SLE cohort Exudative Usually occurs early in course of disease Frequently co-exists with pleurisy Frequently sub clinical Can rarely cause tamponade <1% Hopkins SLE cohort Pulmonary Embolus SLE patients can be hypercoagulable Antiphospholipid antibodies Nephrotic syndrome Anti-dsDNA Antibodies Highly specific for SLE: 90-95% Not very sensitive: 50% In some but not all patients, titers correlate with disease activity, especially renal If titers are negative or unchanged, does not mean that SLE is not active Likewise, if the titers are elevated, does not mean that this patient s chest pain is due to ACTIVE SLE 17
18 SLE: The Seriousness of Chest Pain Infectious complications were classically thought of as leading cause of mortality Growing evidence that ischemic heart disease now leading cause of mortality Risk of CV disease in SLE patients is 7-50 fold greater (dwarfs diabetes and cholesterol and other traditional CV risk factors!!) Cardiac symptoms should be treated seriously in all SLE patients, including young women, and on all board exams!!!! Myocardial Ischemia and SLE: Acute Setting All SLE patients other than those one is CERTAIN do not have CAD, should be evaluated for myocardial ischemia, including obtaining EKG and further workup Hospital setting: telemetry, troponin levels, and appropriate therapy until diagnosis secured Usually not from coronary vasculitis, or other acute SLE activity - but rather from accelerated atherosclerosis in the setting of chronic inflammation Therefore, myocardial ischemia often does not correlate with other SLE activity Chronic Management of CV risk factors Aggressive BP control <130/80 if possible Aggressive cholesterol reduction (LDL<100) Modification of other cardiac risk factors (smoking, exercise, etc ) and use of ASA SLE Chest Pain/SOB Summary Many etiologies of chest pain related to active SLE activity CXR, Chest CT (r/o PE), Echocardiogram, EKG all beneficial in evaluating such a patient depending upon clinical circumstances Keep in mind infectious complications of SLE and therapy that can cause chest pain and/or dyspnea Always treat chest pain in a long standing SLE patient as if it were cardiac ischemia until proven otherwise 18
19 Systemic Lupus Erythematosus Systemic Disorder, involving multiple organs in multiple ways Women:Men = 9:1 African American/Caribbean in US/UK: Dz. is 3 times more common Peak Age of Onset 20 s & 30 s Incidence has tripled since 1970 s to 5.56/100,000 population SLE: ACR Criteria: 4 of 11 Criteria without better explanation (Not diagnostic) Malar Rash Discoid Rash Photosensitivity Oral Ulcers Arthritis Serositis Renal Disorder 19
20 SLE Criteria Cont. Hematologic Disorder Immunologic Disorder ANA Neurologic Disorder Fixed malar distribution of erythema, flat or raised Malar Rash Discoid Rash DLE - Old Erythematous raised patches with keratotic scaling and follicular plugging; some atrophic scarring in chronic lesions 20
21 Photosensitivity Oral Ulcers Skin rash as an unusual reaction sunlight, by patient history or physical examination Oral or nasopharyngeal ulcers, usually painless, observed by a physician Arthritis Other SLE Criteria Non-erosive arthritis involving two or more peripheral joints, characterized by tenderness, swelling, or effusion Serositis Pleuritis (convincing history of pleuritic pain or rub heard by a physician or evidence of pleural effusion Pericarditis (documented by EKG, rub, or evidence of pericardial effusion) Renal Disorder Persistent proteinuria >0.5g/day (or>3+) Cellular casts of any type 21
22 Hematologic Abnormalities Hemolytic anemia (usually coomb s positive) Leukopenia (WBC < 4,000 on at least 2 occasions) Lymphopenia (<1500 on 2 or more occasions) Thrombocytopenia (PLT<100,000 on 2 or more occasions) Immunologic Disorder One of the Following Anti-dsDNA Anti-Smith Positive findings of anti-phospholipid Abs Abnormal level of either IgG or IgM CLIP Abs Positive test for Lupus Anticoagulant (RVVT) False positive RPR/VDRL > 6months neg. FTA Positive ANA An abnormal titer of ANA in the absence of drugs known to be associated with druginduced lupus syndrome Neurologic Disorder Classically defined only as: Seizures (in the absence of other causes) Psychosis (in the absence of other causes) Other CNS manifestations Headaches Cognitive dysfunction 22
23 Organ System Involvement in Flares of SLE, Hopkins Cohort:1991 Constitutional 66% Musculo-skeletal 58% Dermatologic 47% Renal 22% Neurologic 21% Hematologic 17% Serositis 12% Pulmonary 7% Permanent Organ Damage in SLE, Hopkins Cohort: 1991 Musculo-skeletal 25.2% Neuro-psychiatric 15% Ocular 12.6% Renal 11.7% Pulmonary 10.4% Cardiovascular 10.1% GI 7.4% Skin 7.4% Peripheral Vascular 5.5% Malignancy 2.5% Premature Gonadal Failure 1.2% 23
Rheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid
More informationRheumatoid Arthritis. Update in Rheumatoid Arthritis Diagnosis and Therapy. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Update in Rheumatoid Arthritis Diagnosis and Therapy Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid Arthritis Clinic
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationControversies in Women s Health: Clinical Dilemmas in Arthritis
Controversies in Women s Health: Clinical Dilemmas in Arthritis Jonathan Graf, M.D. Assistant Professor of Medicine, UCSF Division of Rheumatology, SFGH December, 2008 Approximate Prevalence of Rheumatic
More informationHigh Impact Rheumatology
High Impact Rheumatology Systemic Lupus Erythematosus Bernard Rubin, DO MPH Case 1: History A 45-year-old woman presents with severe dyspnea and cough. She was in excellent health until 4 weeks ago when
More informationLUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS LUPUS 101 SLE SUBSETS AUTOIMMUNE DISEASE 11/4/2013 HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS
LUPUS 101 LUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS SLE SUBSETS SUBACUTE CUTANEOUS LUPUS DRUG INDUCED LUPUS NEONATAL LUPUS LATE ONSET LUPUS ANTI-PHOSPHOLIPID
More informationRheumatology Primer: What Labs and When
Rheumatology Primer: What Labs and When Irina Konon, MD Department of Internal Medicine Division of Rheumatology Medical College of Wisconsin Disclosures None 1 Objective Discuss principles of laboratory
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationMANAGING THE PATIENT WITH POSITIVE ANA
MANAGING THE PATIENT WITH POSITIVE ANA Rafael F. Rivas-Chacon, M.D. Disclosures Grant/Research support for: Pfizer Study JIA A3921104 Tofacitinib not related to this presentation 1 Positive Antinuclear
More informationRheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care. Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018
Rheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018 No Disclosures Objectives Recognize early signs of RA/PsA what to
More informationEtiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis
Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis JIA is the most common rheumatic disease in childhood and a major cause of chronic disability. Etiology: Unknown, but may
More informationRheumatoid Arthritis. Advances in Biologic Therapies: What the Family Practitioner Should Know. Ra: Traditional Treatment Paradigm
Rheumatoid Arthritis Advances in Biologic Therapies: What the Family Practitioner Should Know Jonathan Graf, M.D. Assistant Professor of Medicine, UCSF Division of Rheumatology, SFGH April, 2008 No Conflicts
More informationAdvances in Laboratory Testing for Rheumatic Diseases Updates in Testing for Rheumatic Diseases. The ABIM s view of rheumatologic lab testing
The black hole of medical knowledge: An internist s view of rheumatologic lab tests Advances in Laboratory Testing for Rheumatic Diseases 2010 Jonathan Graf, M.D. Assistant Clinical Professor of Medicine
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Belimumab Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 11/15/2017 Next
More informationUndifferentiated Connective Tissue Disease and Overlap Syndromes. Mark S. Box, MD
Undifferentiated Connective Tissue Disease and Overlap Syndromes Mark S. Box, MD Overlap Syndromes As many as 25% of patients with rheumatic diseases with systemic symptoms cannot be definitely diagnosed
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More informationSystemic Lupus Erythematosus
Systemic Lupus Erythematosus Marc C. Hochberg, MD, MPH Professor of Medicine and Head, Division of Rheumatology University of Maryland School of Medicine CASE: HISTORY A 26-year-old woman is seen for migratory
More informationRheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011
Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study
More informationSummary Article: Lupus (Systemic Lupus Erythematosus) from Harvard Medical School Health Topics A-Z
Topic Page: Systemic Lupus Erythematosus Summary Article: Lupus (Systemic Lupus Erythematosus) from Harvard Medical School Health Topics A-Z What Is It? Lupus is thought to develop when the immune system
More informationDefinition Chronic autoimmune disease The body s immune system starts attacking itself Can affect most organs and tissues in the body Brain, lungs, he
LIVING WITH SYSTEMIC LUPUS ERYTHEMATOSUS Stacy Kennedy, M.D.,M.B.A. Rowan Diagnostic Clinic Salisbury, N.C. May 11, 2013 Agenda What is lupus Who is affected Causes of lupus Symptoms and organ involvement
More informationIs it Autoimmune or NOT! Presented to AONP! October 2015!
Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationBenlysta (belimumab) Prior Authorization Criteria Program Summary
Benlysta (belimumab) Prior Authorization Criteria Program Summary This prior authorization applies to Commercial, NetResults A series, NetResults F series and Health Insurance Marketplace formularies.
More informationInflammatory rheumatic diseases
Learning objectives Inflammatory rheumatic diseases Bruce Kidd Barts & The London, Queen Mary, University of London To understand: 1. prevalence and range of the rheumatological s 2. clinical features
More informationLupus. Fast facts. What is lupus? What causes lupus? Who gets lupus?
Lupus Systemic lupus erythematosus, referred to as SLE or lupus, is sometimes called the "great imitator." Why? Because of its wide range of symptoms, people often confuse lupus with other health problems.
More informationRheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)
Rheumatoid Arthritis Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) 503-6999. 1 Disclosures Speaker Bureau: Abbvie 2 Objectives Better understand the pathophysiology
More informationA CRP B FBC C LFT D blood culture E uric acid
1 A 39 year old lady with rheumatoid arthritis is admitted to hospital with a hot, swollen and painful right knee. Which is the most important blood test? A CRP B FBC C LFT D blood culture E uric acid
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. Today s Date: Date of HSCT for which this form is being completed: &
Systemic Lupus Erythematosus Pre-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: & HSCT type: o autologous o allogeneic, o
More informationUNDERSTANDING SYSTEMIC LUPUS ERYTHEMATOSUS
UNDERSTANDING SYSTEMIC LUPUS ERYTHEMATOSUS Stacy Kennedy, M.D.,M.B.A. October 20, 2012 Agenda What is lupus Who is affected Causes of lupus Symptoms and organ involvement Diagnosis Treatment Pregnancy
More information9/25/2013 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 1 Other Types of Lupus Discoid Lupus Erythematosus Lupus Pernio --- Sarcoidosis Lupus Vulgaris --- Tuberculosis of the face Manifestations of SLE Fever Rashes Arthritis
More informationEssential Rheumatology. Dr Ellen Bruce Consultant Rheumatologist CMFT
Essential Rheumatology Dr Ellen Bruce Consultant Rheumatologist CMFT Saving the best for last! Apparently people recall best the first and last thing they re told. Far too difficult to include everything.
More informationMedical Management of Rheumatoid Arthritis (RA)
Medical Management of Rheumatoid Arthritis (RA) Dr Lee-Suan Teh Rheumatologist Royal Blackburn Hospital Educational objectives ABC Appreciate the epidemiology of RA Be able to diagnosis of RA Competent
More informationWhen is it Rheumatoid Arthritis When to Refer
When is it Rheumatoid Arthritis When to Refer Nancy A. Brown, DO Spring 2015 When is it Rheumatoid Arthritis When to Refer Learning objectives To review the definition and epidemiology of Rheumatoid Arthritis
More informationSLE and the Antiphospholipid Syndrome
SLE and the Antiphospholipid Syndrome Susan Y. Ritter MD, PhD Associate Physician Division of Rheumatology, Immunology and Allergy Department of Medicine Brigham and Women s Hospital Instructor in Medicine
More informationLUPUS (SLE) MEDICAL SOURCE STATEMENT
LUPUS (SLE) MEDICAL SOURCE STATEMENT From: Re: (Name of Patient) (Social Security No.) Please answer the following questions concerning your patient s impairments. Attach relevant treatment notes, radiologist
More information.,Dr Ali Alkazzaz Babylon collage of medicine 2016
.,Dr Ali Alkazzaz Babylon collage of medicine 2016 Lupus history Lupus is the Latin word for wolf 1 st used medically in the 10 th century Described clinically in the 19 th century Butterfly rash in 1845
More informationMary Derlacki, FNP. No financial relationships to disclose. Office Rheumatology for the Nurse Practitioner. Rheumatoid Arthritis
Office Rheumatology for the Nurse Practitioner Mary Derlacki, FNP Drs. Cassell and Boren Eugene, OR 541-687-0816 mderlacki@comcast.net No financial relationships to disclose Rheumatoid Arthritis 1% of
More informationObjectives. Joint Pain. Case 1. Rheumatology for the Primary MD (Not just your grandmother s disease) 12/4/2010
Objectives Rheumatology for the Primary MD (Not just your grandmother s disease) Identify when it is appropriate to refer for rheumatologic evaluation Autoimmune/ Inflammatory v. noninflammatory disease
More informationRheumatology for the Nurse Practitioner. Mary Derlacki, FNP Eugene Rheumatology
Rheumatology for the Nurse Practitioner Mary Derlacki, FNP Eugene Rheumatology Financial Relationships Amgen Genentech AbbVie IS THIS LUPUS? S.T. is a 45 y/o woman with 9 months of joint pain, fatigue,
More informationDisclosures. Rheumatological Approaches to Differential Diagnosis, Physical Examination, and Interpretation of Studies. None
Rheumatological Approaches to Differential Diagnosis, Physical Examination, and Interpretation of Studies Sarah Goglin MD Assistant Professor of Medicine Division of Rheumatology Disclosures None 1 [footer
More informationHigh Impact Rheumatology
High Impact Rheumatology Evaluation and Management of Rheumatoid Arthritis Rheumatoid Arthritis: Key Features Symptoms >6 weeks duration Often lasts the remainder of the patient s life Inflammatory synovitis
More informationSystemic lupus erythematosus in a male patient
IOP Conference Series: Earth and Environmental Science PAPER OPEN ACCESS Systemic lupus erythematosus in a male patient To cite this article: H Sibarani and Z Zubir 2018 IOP Conf. Ser.: Earth Environ.
More informationArthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS
Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS Introduction: There is perhaps no rheumatic disease that evokes so much fear and confusion among both patients
More informationDISCUSSION BY: Dr M. R. Shakeebi, MD, Rheumatologist
Case presentations Related to some Rheumatic Diseases Lab & Clinic i Programs, Tuesday, April 24, 2012 COORDINATOR: Dr M. Mahdi Mohammadi, LMD,PhD, Immunologist COORDINATOR: Dr M. Mahdi Mohammadi, LMD,PhD,
More informationRheumatologic Lab Tests
Rheumatologic Lab Tests What the Practitioner Needs to Know Mary Nakamura M.D. 2008 Rheumatologic Lab Tests Are rarely diagnostic of any specific disease If you do not have in mind a rheumatologic disease
More informationRheumatoid Arthritis
Rheumatoid Arthritis What is rheumatoid arthritis? Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Rheumatoid arthritis can also cause inflammation of
More informationONE of the following:
Medical Coverage Policy Belimumab (Benlysta) EFFECTIVE DATE: 01 01 2012 POLICY LAST UPDATED: 11 21 2017 OVERVIEW Belimumab (Benlysta ) is indicated for the treatment of adult patients with active, autoantibody-positive,
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationRheumatoid Arthritis Update
Rheumatoid Arthritis Update Beth Valashinas, DO, FACOI, FACR Disclosures Speaker for AbbVie Pharmaceuticals Learning Objectives Upon completion of this session, participants should be able to discuss:
More informationInsights into the DX of Pediatric SLE
Insights into the DX of Pediatric SLE Dr. John H. Yost Pediatric Rheumatology Children s Hospital at Dartmouth Assistant Professor of Medicine Geisel School of Medicine at Dartmouth john.h.yost@hitchcock.org
More informationMMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi
MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More informationAPPROACH TO PATIENTS WITH POLYARTHRALGIA
APPROACH TO PATIENTS WITH POLYARTHRALGIA Scott Vogelgesang, MD Division of Immunology University of Iowa No conflicts of interest DEFINITIONS Arthralgia joint pain with no evidence of inflammation Arthritis
More informationRheumatology Cases for the Internist
Rheumatology Cases for the Internist Marc C. Hochberg, MD, MPH Professor of Medicine Head, Division of Rheumatology and Clinical Immunology Vice Chair, Department of Medicine University of Maryland School
More informationRheumatoid arthritis
1 P a g e Rheumatoid arthritis Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that may affect many tissues and organs, but principally attacks flexible (synovial) joints, and it's
More informationIntroduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis
Rheumatoid Arthritis Stuart Weisman, MD Boulder Medical Center, P.C. 303-622-3724 Introduction What is rheumatoid arthritis? How is it different than arthritis? What are the symptoms? How is it diagnosed?
More informationCSTAR CASE STUDIES: BLOCK F Type 3 Hypersensitivity Reaction
CSTAR CASE STUDIES: BLOCK F Type 3 Hypersensitivity Reaction Setting: ER Mr. Smith I ve just felt so weak for so long, and I ve lost so much weight, and now I m having trouble breathing it s affecting
More informationThe Role of the Physician Assistant in the Management of the RA Patient
For your information Clinical Professor of Medicine, David Geffen School of Medicine at UCLA Private practice, Tustin CA Investigator in clinical trials relevant to this lecture including: anti-tnf for
More informationConflict of Interest. Systemic Lupus Erythematosus and the Antiphospholipid Syndrome Bonnie L. Bermas, MD Brigham and Women s Hospital.
Systemic Lupus Erythematosus and the Antiphospholipid Syndrome Bonnie L. Bermas, MD Brigham and Women s Hospital Conflict of Interest Disclosures: None Overview Diagnostic Classification Criteria of SLE
More information2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.
Making Room for Rheumatology James J. Nocton, MD Disclosures I have nothing to disclose Rheumatic Diseases of Childhood Juvenile Idiopathic Arthritis (JIA) Systemic Lupus Erythematosus (SLE) Juvenile Dermatomyositis
More informationDr. Venkateswari. R. Dr. Janani Sankar s unit Kanchi Kamakoti CHILDS Trust Hospital
Dr. Venkateswari. R. Dr. Janani Sankar s unit Kanchi Kamakoti CHILDS Trust Hospital Acknowledgements: KKCTH Dr. Ramkumar Consultant Dermatologist Dr. Ramprakash Consultant Ophthalmologist Dr. Prasad Manne
More informationPolicy. Section: Medicine Effective Date: January 15, 2015 Subsection: Pathology/Laboratory Original Policy Date: December 5, 2014 Subject:
Last Review Status/Date: December 2014 Page: 1 of 10 Summary Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease that can be difficult to diagnose because patients often present
More informationLiving with Lupus: An Insider s Perspective
Living with Lupus: An Insider s Perspective Pamela Thorpe, MD, FACP Lupus Foundation of America, Inc. Philadelphia Tri-State Chapter Volunteer May 2014 My Own Story Is it Lupus Yet? The What What is this?
More informationAutoimmune diseases. SLIDE 3: Introduction to autoimmune diseases Chronic
SLIDE 3: Introduction to autoimmune diseases Chronic Autoimmune diseases Sometimes relapsing : and remitting. which means that they present as attacks Progressive damage Epitope spreading more and more
More informationCardiothoracic Manifestations of Connective Tissue Disease
Cardiothoracic Manifestations of Connective Tissue Disease Carole Dennie MD FRCPC Professor of Radiology and Medicine Head, Thoracic and Cardiac Imaging Sections The Ottawa Hospital Co-director Cardiac
More informationThe Power of the ANA. April 2018 Emily Littlejohn, DO MPH
Emergent Rheumatologic Diseases and Disorders for Primary Care. The Power of the ANA April 2018 Emily Littlejohn, DO MPH Question 1: the ANA test is: A) A screening test with high specificity to diagnose
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abatacept, for rheumatoid arthritis, 789 Acetaminophen, for low back pain, 735 Acupuncture for fibromyalgia, 753 for low back pain, 738
More informationDevelopment of SLE among Possible SLE Patients Seen in Consultation: Long-Term Follow-Up. Disclosures. Background. Evidence-Based Medicine.
Development of SLE among Patients Seen in Consultation: Long-Term Follow-Up Abstract # 1699 May Al Daabil, MD Bonnie L. Bermas, MD Alexander Fine Hsun Tsao Patricia Ho Joseph F. Merola, MD Peter H. Schur,
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. Today s Date: Date of HSCT for which this form is being completed:
Juvenile Idiopathic Arthritis Pre-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic, allogeneic,
More informationERROR CORRECTION FORM
Juvenile Idiopathic Arthritis Pre-HSCT Data Sequence Number: Registry Use Only Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic, allogeneic, syngeneic unrelated related
More informationRheumatology Review Update in Internal Medicine COPYRIGHT. Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center.
Rheumatology Review Update in Internal Medicine Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center Boston MA Case #1 True statement(s) regarding etanercept and leflunomide, for the treatment
More informationLearning about Lupus. Learning About Lupus. Lupus Society of Illinois
Learning About Lupus Learning about Lupus Lupus Society of Illinois 525 W. Monroe Street, Suite 900 Chicago, Illinois 60661 Robert S. Katz, M.D. Professor of Medicine Rush University Medical Center Northwestern
More informationPain or stiffness in joints after periods of inactivity or excessive use
Arthritis Awareness* Some older adults call it Arthur ; others refer to it as their constant compassion, but most describe it as extremely painful Arthritis is a chronic joint disease It is commonly believed
More informationAutoimmune Disease. Autoimmunity. Epidemiology. ACR Criteria for Diagnosis. Signs and Symptoms. Autoreactivity: Reactivity to self antigens:
Autoimmunity Reactivity to self antigens: Autoreactivity: Autoimmune Disease T cells B cells Leading to tissue damage or dysfunction Occurring in the absence of ongoing infection Epidemiology SLE Pathogenesis
More informationAutoimmunity. Autoimmune Disease
Autoimmunity Reactivity to self antigens: T cells B cells Autoimmune Disease Autoreactivity: Leading to tissue damage or dysfunction Occurring in the absence of ongoing infection 1 SLE Pathogenesis Immune
More informationSystemic lupus erythematosus (SLE) ... PRESENTATIONS... Epidemiology of Systemic Lupus Erythematosus. Based on a presentation by Susan Manzi, MD, MPH
... PRESENTATIONS... Epidemiology of Systemic Lupus Erythematosus Based on a presentation by Susan Manzi, MD, MPH Presentation Summary Tracking the epidemiology of systemic lupus erythematosus is problematic
More informationSLE-key Case Studies
SLE-key Case Studies Ellen M. Field, M.D. Lehigh Valley Health Network, Bethlehem, PA Donald E. Thomas, Jr., M.D., FACP, FACR, RhMSUS, CCD Arthritis and Pain Assoc. of PG County, Greenbelt, MD Case Study
More informationManifestations and Presentations of Collagen Vascular Diseases. Joseph LaConti, M.D., Ph.D. Center for Arthritis and Rheumatic Diseases Miami, FL
Manifestations and Presentations of Collagen Vascular Diseases Joseph LaConti, M.D., Ph.D. Center for Arthritis and Rheumatic Diseases Miami, FL June 29, 2018 Disclosures Joseph LaConti, M.D., Ph.D., has
More informationDemystifying. Systemic Lupus Erythematosus: Signs and Symptoms for Early Recognition. Teaching Fellows in Lupus Project
Demystifying Systemic Lupus Erythematosus: Signs and Symptoms for Early Recognition Teaching Fellows in Lupus Project Introduction: Why are we here? Lupus can take 4-6 years and 3 providers before diagnosis*
More informationScott Vogelgesang, MD Division of Rheumatology/Immunology University of Iowa
Scott Vogelgesang, MD Division of Rheumatology/Immunology University of Iowa Basic Concepts ANA DsDNA Sm RNP SSA SSB RF/CCP ESR/CRP ANCA Cases Summary Rheumatology Tests Lie and Mislead! Rheumatology Rally
More informationInflammatory arthritis Shared Decision Making
Inflammatory arthritis Shared Decision Making DMARDs El Miedany et al. Ann Rheum Dis 74(Suppl2): 1002 DOI: 10.1136/annrheumdis-2015-eular.1410 www.rheumatology4u.com Copyrights reserved Contents 1 2 3
More informationHow do polyarthritis, polyarthralgias, and diffuse aches and pains differ?
Approach to the patient with polyarthritis How do polyarthritis, polyarthralgias, and diffuse aches and pains differ? Polyarthritis is definite inflammation (swelling, tenderness, warmth) of more than
More informationPediatric Rheumatology: A Case-based Approach to the Basics. Hilary M. Haftel, MD, MHPE University of Michigan Department of Pediatrics
Pediatric Rheumatology: A Case-based Approach to the Basics Hilary M. Haftel, MD, MHPE University of Michigan Department of Pediatrics Disclosures I have no relevant financial relationships with the manufacturer(s)
More informationSystemic Lupus Erythematosus
A Patient s Guide to Systemic Lupus Erythematosus 2 kidneys. These changes make it impossible for the kidneys to function normally. The inflammation of SLE can be seen in the lining, covering, and muscles
More informationSystemic examination
PROLONGED FEVER IN AN ADOLESCENT BOY Dr.Praveena Lionel, DNB PG, Dr.Kannan (HOD) Railway Hospital, Perambur History 11 yrs old adolescent boy was admitted with c/o Fever -1 wk Myalgia -1 wk Arthralgia
More information10/6/08. Systemic Lupus Erythematosus. SLE Epidemiology: who is at risk? Margrit Wiesendanger Division of Rheumatology, CUMC.
Systemic Lupus Erythematosus SLE Epidemiology: who is at risk? One of the most common autoimmune diseases affecting women of all ages Predominantly women in child-bearing years (M:F ratio is 1:10) Incidence
More informationRheumatoid Arthritis in Asians
NO DISCLOSURES Rheumatoid rthritis in sians Mary C. Nakamura M.D. Professor of Medicine, UCSF Rheumatoid rthritis Rheumatoid rthritis Polyarthritis of synovial lined joints Inflammatory Characteristic
More informationJeopardy. What s the rash? $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400
Jeopardy Antibodies & more antibodies Aching joints What s the rash? Potpourri Image Challenge $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400 $500 $500
More informationEARLY INFLAMMATORY ARTHRITIS. Cristina Tacu Consultant Rheumatologist Brighton and Sussex University Hospital
EARLY INFLAMMATORY ARTHRITIS Cristina Tacu Consultant Rheumatologist Brighton and Sussex University Hospital EIA: Introduction National priority Preventable cause of disability Very common condition High
More informationAUTOIMMUNITY CLINICAL CORRELATES
AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel
More informationAUTOIMMUNITY TOLERANCE TO SELF
AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel
More informationRheumatoid Arthritis Update. Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy
Rheumatoid Arthritis Update Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy Disclosures I declare that neither I nor any member of
More informationJuvenileIdiopathicArthritis. Dr Johan Siebert
JuvenileIdiopathicArthritis Dr Johan Siebert 1 NORMAL DIARTHRODIAL JOINT Synovial is a thin membrane enclosing the joint space The joint space contains fluid that bathes the joint and reduces friction
More informationRheumatology Updates for the Primary Care Provider
Rheumatology Updates for the Primary Care Provider Jean Tayar, MD, RhMSUS Associate Professor Section of Rheumatology and Clinical Immunology Department of General Internal Medicine UT MD Anderson Cancer
More informationRheumatoid Arthritis. Ajay Bhatia Rheumatology Consultant Hillingdon Hospital
Rheumatoid Arthritis Ajay Bhatia Rheumatology Consultant Hillingdon Hospital ajay.bhatia@thh.nhs.uk Rheumatoid Arthritis When to refer to secondary care? Why early referral is beneficial for the patient?
More informationAdult-onset Still s disease a polygenic autoinflammatory disease
Adult-onset Still s disease a polygenic autoinflammatory disease Tom Pettersson, MD, PhD University of Helsinki and Helsinki University Central Hospital IL-1 mediated diseases past present and future Såstaholm
More informationSystemic Lupus Erythematosus (SLE) Epidemiology of SLE (United States)
1:10-2:25pm Closing the Loop on Lupus: Primary Care s Key Role in the Elusive Diagnosis and Management of Patients SPEAKER Richard Sadovsky, MD Richard Furie, MD Disclosures This session is supported by
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationSupplementary material
Supplementary material Table S1: Dubois Guidelines for Diagnosis of DrugInduced Lupus 1. Continuous treatment with a known lupusinducing drug for 1month and usually much longer 2. Presenting symptoms:
More information